Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07056036 · ClinicalTrials.gov registry record · NA
EXOMIND (BTL-699-2) for the Improvement in Willpower & Food Cravings
A NA study of Self-Control and Food Cravings, sponsored by BTL Industries.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
- 4
- Study locations
NCT07056036: Completed NA study of Self-Control and Food Cravings, sponsored by BTL Industries.
NCT07056036 is a NA study of Self-Control and Food Cravings that has completed, run by BTL Industries. The registered enrollment target is 51 participants, below the 555-participant average among 3 other Self-Control trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07056036, a NA study of Self-Control and Food Cravings, has completed, sponsored by BTL Industries.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to evaluate if the treatment with ExoMIND (BTL-699-2) device is able to improve willpower, self-control and food cravings in adults above the age of 22 years. The main question it aims to answer is: Does the treatment with EXOMIND (BTL-699-2) device improve willpower, self-control and food cravings? Participants will be asked to: * Undergo six treatments * Complete the Brief Self-control Scale * Complete the Food Cravings Questionnaire - Trait * Complete the Therapy Comfort Questionnaire * Complete the Subject Satisfaction Questionnaire
Primary Outcome
The change in the score obtained from the Brief Self-Control scale will be recorded. The questionnaire will be administered at the baseline visit, after the last treatment, at the 1-month and 3-month follow-up visits. The score ranges from 13 to 65 and higher scores indicate a higher level of self-control. An improvement is defined as an increase in score.
Conditions Studied
Interventions
- DEVICE ActiveTreatment with BTL-699-2
- DEVICE Sham Treatment with BTL-699-2
Study Locations (4)
Colorado
- Aria Integrative Health - Denver
Florida
- A New You Wellness - Miami
Indiana
- Cady Wellness Institute - Newburgh
Ohio
- Jiva Med Spa - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2025-10-10 |
| Phase | NA |
What the finished NCT07056036 record still lists
NCT07056036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 555-participant average among 3 other Self-Control trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Self-Control appearing as the primary indexed condition, and to 2 interventions - of which ActiveTreatment with BTL-699-2 is the first listed.
NCT07056036 reports a single indexed study location in Colorado, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT07056036 about?
NCT07056036 is a clinical study titled "EXOMIND (BTL-699-2) for the Improvement in Willpower & Food Cravings". The goal of this clinical trial is to evaluate if the treatment with ExoMIND (BTL-699-2) device is able to improve willpower, self-control and food cravings in adults above the age of 22 years. The main question it aims to answer is: Does the treatment with EXOMIND (BTL-699-2) device improve willpo...
What is the current status of trial NCT07056036?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2024-11-01. Estimated completion is 2025-10-10.
What conditions does trial NCT07056036 study?
This clinical trial studies the following conditions: Self-Control, Food Cravings.
What interventions are being tested in trial NCT07056036?
The interventions under investigation include: ActiveTreatment with BTL-699-2 (DEVICE), Sham Treatment with BTL-699-2 (DEVICE).
Who is sponsoring clinical trial NCT07056036?
This trial is sponsored by BTL Industries, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07056036 being conducted?
This trial has 4 study locations across Colorado, Florida, Indiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Self-Control
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI